Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disease.
Before progressing to AD, individuals may experience mild cognitive impairment (MCI). While
these individuals with MCI have an increased risk of progressing to AD, emerging studies
reveal that obstructive sleep apnea (OSA) is a risk factor for both MCI an well as AD. Thus,
it is worthwhile to identify clinical management or interventions that retard the conversion
of subjects with comorbid MCI and OSA and AD.
A randomized, double-blind, placebo-controlled study proposed herein aims to examine the
effect of trazodone on reducing level sST2 and protein markers that are associated with
neurodegeneration in the plasma of subjects with comorbid OSA and MCI. In this 1-year study,
124 study participants will undergo a series of neurocognitive assessments.